Comparing Two Chemotherapy Regimens for Metastatic Breast Cancer
Author Information
Author(s): J-Y Pierga, M Jouve, B Asselain, A Livartowski, P Beuzeboc, V Dieras, S Scholl, T Dorval, T Palangie, E Garcia-Giralt, P Pouillart
Primary Institution: Institut Curie
Hypothesis
Is continuous infusion of 5-fluorouracil more effective than bolus administration in treating metastatic breast cancer?
Conclusion
Both chemotherapy regimens were equally effective, but the continuous infusion regimen had lower toxicity.
Supporting Evidence
- Response rates were 54% in the FAC arm and 53% in the FULON arm.
- Median overall survival duration for all patients was 22 months.
- Haematological toxicity was more severe in the bolus-treated group.
Takeaway
Doctors tested two ways to give medicine to women with advanced breast cancer and found both worked about the same, but one way made them feel less sick.
Methodology
258 women with metastatic breast cancer were randomly assigned to receive either a bolus or continuous infusion of chemotherapy, and their responses were evaluated over time.
Limitations
The study did not assess the dose intensity of doxorubicin delivered in the continuous infusion regimen.
Participant Demographics
All participants were women with histologically confirmed metastatic breast cancer, aged over 18.
Statistical Information
P-Value
P < 0.01 for nausea and vomiting; P = 0.05 for haematological toxicity.
Want to read the original?
Access the complete publication on the publisher's website